Kamada Ltd. (NASDAQ:KMDA) is a global biopharmaceutical company that focuses on developing treatments for rare and serious conditions. The company operates in the Zacks Medical - Biomedical and Genetics industry. Kamada has recently been in the spotlight due to a price target set by Annabel Samimy from Stifel Nicolaus, who projected the stock to reach $11, indicating a potential upside of 28.73% from its current price of $8.54, as highlighted by StreetInsider.
Despite the optimistic price target, Kamada's recent financial performance has shown mixed results. The company reported a fourth-quarter profit of $0.06 per share, which was below the Zacks Consensus Estimate of $0.09 per share. This earnings report marked a 30.8% negative surprise and a decline from the $0.07 per share reported in the same quarter last year. Over the past four quarters, Kamada has only exceeded consensus EPS estimates once.
In terms of revenue, Kamada generated $44.68 million for the quarter ending December 2025, which was 2.29% below the Zacks Consensus Estimate. However, this was an improvement from the $39.01 million in revenue reported in the same period the previous year. For the full year 2025, Kamada achieved a record revenue of $180.5 million, marking a 12% increase compared to the previous year. The company's adjusted EBITDA rose by 23% to $42 million, while net income surged by 40% to $20.2 million.
Looking forward, Kamada has set a positive outlook for 2026, projecting revenues between $200 million and $205 million, alongside an adjusted EBITDA ranging from $50 million to $53 million. This forecast represents continued double-digit organic growth. Kamada is also focusing on securing new business development and mergers and acquisitions to further accelerate its profitable growth. The company has adopted an annual cash dividend policy and declared a cash dividend of $0.25 per share, amounting to approximately $14.4 million in total.
Kamada's stock is currently trading at $8.54, reflecting a decrease of 4.69% or $0.42. The stock has traded between a low of $8.41 and a high of $8.70 today. Over the past year, KMDA has reached a high of $9.35 and a low of $5.54. The company's market capitalization stands at approximately $492.6 million, with a trading volume of 203,718 shares on the NASDAQ exchange.
